<DOC>
	<DOCNO>NCT00730405</DOCNO>
	<brief_summary>Phase 2 study examine study drug work side effect subject toenail fungus .</brief_summary>
	<brief_title>Efficacy Safety Study 4 Dose Regimens Oral Albaconazole Subjects With Distal Subungual Onychomycosis</brief_title>
	<detailed_description>A phase 2 , randomize , double-blind , placebo-controlled , parallel-group , dose-ranging study investigate efficacy safety 4 dose regimen ORAL albaconazole subject distal subungual onychomycosis . Subjects take oral study drug 36 week follow additional 16 week determine study drug efficacious . Subjects routine blood draw safety assessment study , well regular assessment toenail fungus</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<criteria>Subject age 18 75 year . Diagnosis distal subungual onychomycosis toenail affect least one great toe ( target toenail ) . Subject willing provide sign dated write voluntary inform consent ( local national authorization requirement ) protocolspecific procedure perform . Subject able complete study , comply study instruction , take study product orally . Sexually active nonlactating female childbearing potential participating study must agree use medically acceptable method contraception receive protocolassigned product first menses 60 day follow last dose study product . Women childbearing potential must negative pregnancy test enrollment . Subject screen laboratory parameter ECG within normal range unless consider clinically relevant principal investigator . Subjects follow condition characteristic exclude study enrollment ( ie , receive study product ) : Subject receive investigational drug within 4 week first dose study product , schedule receive investigational drug study product study . Subject participate clinical trial systemic treatment onychomycosis toenail within 6 month prior first dose study product . Subject receive drug know substrate 3A4 isozyme cytochrome P450 ( CYP3A4 ) QT prolongation potential concomitant medication list prohibited medication section . Subject history know suspected intolerance albaconazole formulation excipients , azole antifungal drug general . Subject previously participate clinical study albaconazole . Subject prepared give use nail cosmetic product duration study . Subject known immunodeficiency history malignancy last 4 year , exclude nonmelanoma skin cancer . Subject know liver disease history liver toxicity drug . Subject currently suffer disease condition , could include abnormal laboratory test , and/or currently use medication opinion investigator may affect evaluation study product place subject undue risk . Subject psoriasis , lichen planus , abnormality could result clinically abnormal toenail . Subject history condition could possibly affect absorption drug ( eg , gastrectomy ) , uncontrolled diabetes , clinically significant peripheral vascular disease peripheral circulatory impairment , major illness within 30 day prior screen examination . Subject history drug , prescription medicine , alcohol abuse within past 2 year . Female subject pregnant , try become pregnant , lactate . Employees Investigator/clinical research organization ( CRO ) Stiefel Laboratories , Inc. , immediate family member ( partner , offspring , parent , sibling sibling 's offspring ) employee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Distal , Subungual onychomycosis</keyword>
	<keyword>onychomycosis</keyword>
	<keyword>nail fungus</keyword>
	<keyword>Toenail fungus</keyword>
</DOC>